Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Lilly

Brain power: fresh approaches to Alzheimer’s drug discovery

New alliances are learning from past mistakes and breaking down research barriers

Biogen Idec building

Biogen, Eisai cue up BAN2401 readout in Alzheimer’s in 2022

Also considering a trial in preclinical Alzheimer’s subjects

Eli Lilly HQ

Lilly, Pfizer say NGF drug works in back pain too

Tanezumab was able to show a statistically significant improvement in pain

- PMLiVE

GW Pharma’s cannabis-based medicine to be tested in dementia

Trial will be funded by Alzheimer’s Research UK

- PMLiVE

Another amyloid bust as Roche pulls crenezumab trials

Undermines amyloid hypothesis hopes. including Biogen candidate

- PMLiVE

Researchers reverse Alzheimer’s memory loss in mice

Epigenetics opens up new potential drug targets

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?

Healthcare leaders in the European Union should begin preparing for a breakthrough now

- PMLiVE

Lilly partners with AC Immune on tau drug for Alzheimer’s

Potential payments of $1.7bn to Swiss firm

- PMLiVE

Theranexus takes Alzheimer’s drug combo into clinic

150-subject phase 1b trial to start at eight centres in France

- PMLiVE

Tox trouble stalls Sosei/Allergan Alzheimer’s drug

Surprise findings from primate studies

Biogen Idec building

Big debate follows Biogen/Eisai’s Alzheimer’s study unveiling

Mixed results prompted a 10% share drop for both companies

- PMLiVE

Daily Brief: Janssen’s HIV vaccine, Q2 results, Biogen’s Alzheimer’s data

News from pharma, biotech and healthcare

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links